The room on the screen shifted. Clare did not raise her voice, but every word carried the weight of a judge passing sentence.

"You told me it was the Series B funding round," Clare said to the camera, her dark eyes reflecting the harsh glow of her laptop screen. "You said the venture capitalists in London were demanding an emergency alignment call. I sat in the recovery room, bleeding, shaking from the epidural, holding my breath because our son’s lungs were failing inside an incubator three floors away. I called your cell six times. When you finally picked up, I could hear jazz music in the background. You told me I was being hysterical. You told me the stress was going to dry up my milk."

Grant’s hand gripped the edge of his desk so hard his knuckles turned white.

He remembered that night. He remembered standing in the lobby of the Gramercy Park Hotel with a glass of scotch in one hand, whispering into his phone that Clare needed to calm down for the baby's sake. He had convinced himself he was right. He had convinced himself that running Ashford Biotech required sacrifices that a woman wrapped up in domesticity could never comprehend.

"I believed you," Clare whispered on the video. "Or rather, I wanted to believe you. Because the alternative meant admitting that the man I had given seven years of my life to—the man who held my hand while we picked out wallpaper for the nursery—was a stranger who viewed our family as a PR asset."

She reached out and clicked something off-screen.

The video minimized, revealing a detailed PDF document. Grant’s eyes scanned the lines. It was a comprehensive asset audit. Corporate shell companies in Delaware. Offshore accounts in the Caymans. Real estate holdings in Miami and Zurich that Clare’s name had never been attached to—until now.

Beneath the financial trail was a new folder: Nathan Cross.

Grant frowned. He clicked it.

A dossier opened. Photographs of a man in his late thirties with sharp, intelligent eyes, a bespoke suit, and a law degree from Columbia. Nathan Cross wasn't just any lawyer; he was the senior partner at Cross & Sterling, a firm legendary for handling high-net-worth corporate dissolutions and asset freezes that left executives financially paralyzed before they even realized they were under attack.

Grant’s phone buzzed on the mahogany desk.

It wasn't a call. It was a push notification from his corporate bank.

Alert: Wire transfer initiated from Corporate Operating Account ending in 4892 to Trust Account Client #8841. Amount: $4,250,000. Status: Pending Authorization.

Grant laughed—a harsh, disbelieving sound that echoed in the empty penthouse.

"Nice try, Clare," he muttered to the empty room. "You can’t freeze corporate funds with a civil petition. You don't have the signature authority."

His phone buzzed again.

Alert: Corporate Board Resolution #2026-44 received.

Grant opened his email app with trembling fingers. Attached was a document bearing the signatures of three independent board members—including Arthur Vance, Grant’s oldest ally and the co-founder of Ashford Biotech.

The subject line read: Emergency Suspension of CEO / Succession Trigger Activated.

Grant tapped the PDF. Arthur Vance’s signature was crisp, legal, and absolute. Based on "credible allegations of corporate malfeasance, asset dissipation, and fiduciary negligence," the board had voted unanimously at 4:30 AM—while Grant was still riding in the back of an Uber from Vanessa’s apartment—to strip him of his executive powers.